Ärzteblatt8d
App-based psychotherapy of panic disorder with self-guided exposure in virtual reality—a randomized, controlled trial
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published. Klinik für Psychiatrie und Psychotherapie ...
Ärzteblatt6d
Atretic cephalocele as the cause of swelling on the head of an infant
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.
Ärzteblatt5d
The prevalence of lonely deaths and suicides in the home—an analysis of death certificates and emergency physician protocols
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published. 1. Deutscher Hospiz- und PalliativVerband e. V. (DHPV ...
Ärzteblatt6d
The prevalence of lonely deaths and suicides in the home—an analysis of death certificates and emergency physician protocols
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.
Ärzteblatt6d
Contacts of health care companies with guideline coordinators—a cross-sectional survey
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.
Ärzteblatt5d
Contacts of health care companies with guideline coordinators—a cross-sectional survey
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published. Charité – Universitätsmedizin Berlin, corporate member ...
Ärzteblatt7d
Evaluation of an automated decision aid for the further referral of emergency room patients
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published. Notfallmedizinische Versorgungsforschung, Notfall –und ...
Ärzteblatt25m
Multiples Myelom: Talquetamab plus Teclistamab erzielt häufig Remissionen
Tel Aviv – Die beiden BiTE-Antikörper Talquetamab und Teclistamab, die 2023 zur Behandlung des Multiplen Myeloms zugelassen ...